04/16/2024

Tempus Introduces its AI-enabled Care Pathway Intelligence Platform, Tempus Next

Tempus, a leader in artificial intelligence and precision medicine, is introducing Tempus Next, a care pathway intelligence platform. By harnessing the power of AI, Tempus Next identifies care gaps and equips clinicians with actionable insights at the point of care, supporting access to the most up-to-date, guideline-directed treatments.

Tempus Next is designed to accelerate the adoption of precision medicine and enhance patient outcomes. The solution integrates seamlessly with EMRs in order to analyze a comprehensive suite of data—including clinical notes, molecular information, and imaging—to pinpoint deviations from care guidelines. Participating health systems receive regular updates, enabling them to maintain high care quality standards and track patient outcomes effectively.

“Given that Tempus is now connected in near real time to more than 50% of all oncologists in the U.S., we have the ability to deploy AI solutions at a scale that has historically not been possible,” said Eric Lefkofsky, CEO and Founder of Tempus. “The increasing complexity of guidelines and the compounding data that physicians need to access in order to treat their patients has created a growing number of care gaps. Next is designed to help close those gaps by seamlessly notifying care teams when a guideline or standard is not being followed, so that every patient has access to the personalized attention and treatment they deserve.”

Tempus has extensive experience delivering care pathway intelligence in cardiology, with over sixty care pathway intelligence algorithms in cardiovascular disease currently deployed across more than eighty hospitals. Tempus Next has expanded into oncology, starting with lung cancer and breast cancer, with a number of leading institutions.

“We are at the cusp of a healthcare transformation, and with Tempus Next, we anticipate setting a new standard for patient care,” said Andrew Parchman, MD, Precision Oncology Medical Director, Medical Oncologist, TriHealth Cancer Institute. “This platform’s ability to notify us of care gaps and guide evidence-based decisions in real time aligns perfectly with our mission to deliver personalized, proactive treatment to every patient.”

“The Tempus Next platform has revolutionized patient care by delivering actionable insights in real time,” said Abhinav B. Chandra, MD, Medical Director, Yuma Regional Medical Center Cancer Center. “These insights enable timely adjustments to patient management, ensuring precision and responsive healthcare.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Related Content

View more
  • post image
    06/25/2024

    Revolutionizing Cardiac Care: AI-driven detection and treatment of critical heart valve disease at Boulder Community Health

    Discover how Tempus Next's AI-powered care pathway platform transformed patient outcomes by helping ensure timely, guideline-directed treatment for critical heart valve disease at Boulder Community Health

    Read more
  • post image
    05/24/2024

    ADCs in focus: The next generation of precision medicine in oncology

    Watch this engaging discussion as thought leaders explore the evolving landscape of antibody-drug conjugates (ADCs) in cancer therapeutics, including resistance mutations in first-gen ADCs, combination strategies with immune checkpoint inhibitors (ICIs), and next-gen targets and technologies. Tempus is dedicated to enhancing ADC development by offering comprehensive genomic profiling, multimodal de-identified real-world data (RWD), and AI-enabled solutions, informing target discovery and clinical trial optimization for more personalized therapies.

    Watch replay
  • post image
    06/07/2024

    Advancing transcriptional cancer therapies with Tempus’ comprehensive life science solutions

    Kronos Bio, a trailblazer in the biopharmaceutical industry, is dedicated to the discovery and development of novel therapies that target transcriptional regulation in cancer. Kronos turned to Tempus’ comprehensive suite of solutions to propel its principal asset from discovery to clinical trials.

    LIVE WEBINAR

    Wednesday, July 31 @ 11am CT

    Integrating Omics in R&D: A new era of biomedical research

    Join us as we explore how multi-omics is reshaping the research landscape. Gain valuable insights from industry leaders as we: dive into the integration of diverse omics data, from NGS to proteomics, in research; discuss the transformative role of multi-omics in understanding complex disease mechanisms; and explore how multi-omics is personalizing clinical research for precision medicine.

    Read more